About IntelGenx
IntelGenx is a publicly listed company based in Saint-laurent (Canada) founded in 2003. Oral thin-film technologies are developed for improved drug delivery. IntelGenx has raised $5.23 million across 10 funding rounds from investors including Tilray. IntelGenx offers products and services including VersaFilm, VetaFilm, and VevaDerm. Its focus areas include Life Sciences, Drug Delivery and Diversified. Its legal entity is INTELGENX TECHNOLOGIES CORP.
Company details
IntelGenx was founded in 2003 as a developer of oral thin-film technologies focused on pharmaceutical drug delivery. Proprietary platforms such as VersaFilm, VersaTab, and AdVersa are utilized to enhance the efficacy and bioavailability of medications. Existing drugs are reformulated into rapidly disintegrating films that enable water-free administration and better buccal or sublingual absorption. Operations center on branded product reintroduction in the pharmaceutical sector, with a digital presence at intelgenx.com.
- Headquarters Saint-laurent, Canada
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website intelgenx.com
- Social LinkedIn X Facebook
- Legal Name Intelgenx Technologies Corp.
- Annual Revenue$1.04 M (USD)9as on Dec 31, 2023
- Net Profit-$9.93 M (USD)7as on Dec 31, 2023
- EBITDA-$8.73 M (USD)-1as on Dec 31, 2023
- Total Equity Funding$5.23M (USD)
in 10 rounds
- Latest Funding Round$763K (USD), Debt – Convertible
Mar 2023
- Investors
Products & Services of IntelGenx
IntelGenx offers a comprehensive portfolio of products and services, including VersaFilm, VetaFilm, and VevaDerm.
Rapidly disintegrating films for easy drug administration without water
Buccal films improving drug absorption and reducing side effects
Patches for prolonged drug release and reduced dosing frequency
Funding Insights of IntelGenx
IntelGenx has successfully raised a total of $5.23M across 10 strategic funding rounds. The most recent funding activity was a Debt – Convertible round of $763 thousand completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.23M
- Total Rounds 10
- Last Round Debt – Convertible — $763,000
- First Round $1.73M
(Jun 2011)
- Investors Count 1
All 10 funding rounds of IntelGenx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | $763,000 | Debt – Convertible | – | – | – |
| Sep 2021 | $2.1M | Post-IPO | – | – | – |
| Oct 2020 | $1.76M | Post-IPO | – | – | – |
| Oct 2020 | $1.2M | Post-IPO | – | – | – |
| Jan 2020 | Post-IPO | – | – | – | |
| Nov 2018 | $1M | Post-IPO | – | – | |
| Oct 2018 | $12M | Post-IPO | – | – | – |
| May 2018 | $3.2M | Post-IPO | – | – | – |
| Dec 2013 | $3.5M | Private Equity Round | – | – | – |
| Jun 2011 | $1.73M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in IntelGenx
IntelGenx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Tilray.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Online e-distributor offering cannabis products for medical purposes | 2013 | tilray.com | Leamington, Canada |
Investor details for IntelGenx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of IntelGenx
17 people are tracked at IntelGenx (5 in leadership, 12 in board & advisors).
| Name | Role | Group |
|---|---|---|
Karen Kalayajian | VP, Finance | Leadership |
Dwight Gorham | CEO | Leadership |
Andre Godin | President and CFO | Leadership |
Tommy Kenny | VP, Intellectual Property and Legal Affairs, General Counsel | Leadership |
David Kideckel | SVP & Head, Corporate Development & Strategic Alliances | Leadership |
Ludwig Aigner | Scientific Advisor | Board & advisors |
Clemens Mayr | Director | Board & advisors |
Horst G. Zerbe | Director | Board & advisors |
J. Bernard Boudreau | Director | Board & advisors |
Bernd J. Melchers | Director | Board & advisors |
Mark Nawacki | Director | Board & advisors |
Srinivas G. Rao | Director | Board & advisors |
Frank Stegert | Director | Board & advisors |
Monika Trzcinska | Director | Board & advisors |
Ingrid Zerbe | Corporate Secretary | Board & advisors |
Barry Greenberg | Scientific Advisor | Board & advisors |
Serge Gauthier | Scientific Advisor | Board & advisors |
Complete people profiles for IntelGenx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of IntelGenx
4 dated milestones of IntelGenx across 20 years, from founding to its latest funding, stage changes and deals.
- Founded IntelGenx is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.7M.
- Funding Latest funding round, Debt – Convertible, of $763K.
Web traffic of IntelGenx
Websites that share an audience with IntelGenx (intelgenx.com).
Websites whose visitors overlap most with IntelGenx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cytrx.com | cytrx.com | 100% | – | ||
| altheadx.com | 98% | View details | |||
| idifarma.com | 98% | View details | |||
| primevigilance.com | 98% | 6.5K | #2,449,812 | View details | |
| astx.com | 97% | 8.9K | #2,592,392 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for IntelGenx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Intelgenx
Complete news archive for IntelGenx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about IntelGenx
IntelGenx was founded in 2003 and raised its 1st funding round 8 years after it was founded.
IntelGenx is headquartered in Saint-laurent, Canada. It is registered at Saint-laurent, Quebec, Canada.
IntelGenx is a funded company, having raised a total of $5.23M across 10 funding rounds to date. The company's 1st funding round was a Seed of $1.73M, raised on Jun 2011.
Annual revenue of IntelGenx is $1.04M as on Dec 31, 2023.
IntelGenx was founded in 2003 as a developer of oral thin-film technologies focused on pharmaceutical drug delivery. Proprietary platforms such as VersaFilm, VersaTab, and AdVersa are utilized to enhance the efficacy and bioavailability of medications. Existing drugs are reformulated into rapidly disintegrating films that enable water-free administration and better buccal or sublingual absorption. Operations center on branded product reintroduction in the pharmaceutical sector, with a digital presence at intelgenx.com.
IntelGenx offers VersaFilm, VetaFilm, and VevaDerm.
IntelGenx has 1 investor. Key investors include Tilray.
IntelGenx operates through Intelgenx Technologies Corp..